Boehringer Ingelheim

Boehringer Ingelheim is one of the world’s largest privately owned pharmaceutical companies, dedicated to researching, developing, manufacturing, and commercializing innovative medicines for both human and animal health. Founded in 1885 and headquartered in Ingelheim am Rhein, Germany, the company operates in more than 130 countries and has earned a strong reputation for scientific excellence, innovation, and long-term commitment to healthcare.

The company’s human pharmaceutical portfolio focuses on respiratory diseases, cardiovascular and metabolic disorders, oncology, immunology, neuroscience, and rare diseases. In addition, Boehringer Ingelheim is a global leader in animal health, providing vaccines, therapeutics, and preventive healthcare solutions for livestock and companion animals. The company utilizes advanced biotechnology, genomics, artificial intelligence, digital research platforms, and precision medicine to accelerate the discovery of new treatments.

Boehringer Ingelheim maintains an extensive international network of research centers, manufacturing facilities, and commercial operations, all operating under rigorous global quality standards and regulatory compliance. Sustainability, environmental responsibility, patient-centered innovation, and ethical business practices are core components of its corporate strategy. Through continuous scientific investment and collaboration with academic institutions, biotechnology companies, and healthcare organizations, Boehringer Ingelheim continues to deliver innovative therapies that improve the health and well-being of patients and animals worldwide.